Evidence map›Paper›PMID 40169461›Full record

ArticleHuman cell2025

Establishment and characterization of NCC-OS2-C1: a novel patient-derived cell line of osteosarcoma.

Shuhei Iwata, Rei Noguchi, Julia Osaki, Yuki Adachi, Yomogi Shiota, Koichi Ogura, Shogo Nishino, Akihiko Yoshida, Seiji Ohtori, Akira Kawai and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shuhei IwataDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Rei NoguchiDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Julia OsakiDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Yuki AdachiDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Yomogi ShiotaDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Koichi OguraDepartment of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Shogo NishinoDepartment of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Akihiko YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Seiji OhtoriDepartment of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8670, Japan.
Akira KawaiDepartment of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Tadashi KondoDivision of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. proteomebioinformatics@gmail.com.ORCID http://orcid.org/0000-0001-6405-7792

Funding

the Japan Agency for Medical Research and Development 20ck0106537h
6 · The paper itself

Abstract

Osteosarcoma is the most common primary bone sarcoma with a bimodal age distribution. Complete surgical resection with neoadjuvant chemotherapy is the standard curative treatment, and no effective therapeutic strategy has been established for metastatic cases, resulting in poor prognosis. Osteosarcoma presents complex and heterogeneous clinical and molecular features, and no molecular-targeted drugs are available. Therefore, effective multidisciplinary treatment strategies are urgently required. Patient-derived cell lines are essential tools in basic and translational oncology. Considering the heterogeneity of the disease, we established a novel cell line, NCC-OS2-C1, using surgically resected tumor tissues from a patient with osteosarcoma. NCC-OS2-C1 cells demonstrated constant proliferation, spheroid formation, and invasion. In addition, we demonstrated that NCC-OS2-C1 is applicable for the high-throughput screening of drugs. Thus, NCC-OS2-C1 is a valuable tool for basic and translational research on osteosarcoma.

Indexed as

Bone NeoplasmsOsteosarcomaCell Line, TumorCell ProliferationHumansNeoplasm InvasivenessSpheroids, CellularBone sarcomaCell lineDrug screeningOsteosarcomaPatient-derived cancer model

Identifiers

PMID40169461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.